chevron_leftBack
As of 14 June 2026, iNtRON Biotechnology, Inc. has a market cap of $77.75M USD, ranking #27352 globally and #1402 in South Korea.
It ranks #2457 in the Healthcare sector, and #885 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$77.75MUSD
118.24B KRW
Enterprise Value
$52.57MUSD
79.81B KRW
Revenue (TTM)
$3.77MUSD
5.74B KRW
EBITDA (TTM)
-$3.92MUSD
-5.96B KRW
Net Income (TTM)
-$5.89MUSD
-8.96B KRW
EBITDA Margin
-104%
Profit Margin
-156%
PS Ratio
20.6
PB Ratio
1.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
73
Founded
1999
Website
intron.co.kr
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.5% | -3.7% | -11% | -2% | 3.3% | -8.3% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
048530
(주)인트론바이오테크놀로지
ISIN: KR7048530000
Shares Out.:
Shares Outstanding:
30.17M1
Shares Float:
23.822M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
3,610 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About iNtRON Biotechnology, Inc.
iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.15B
12K%
13.91T KRW
|
-
|
|
KRX: 000250
|
$6.77B
9K%
10.3T KRW
|
1958.1
|
|
KRX: 326030
|
$5.24B
7K%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$4.96B
6K%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.55B
6K%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.44B
6K%
6.76T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
980K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
704K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
464K%
|
97.4
|
|
SIX: RO
|
$321.52B
413K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
371K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
353K%
218.9B CHF
|
20.5
|
chevron_leftBack